Propeller delivers consistent and significant clinical improvements
Propeller’s consistent improvements in disease control and medication adherence are seen across diverse patient populations, settings and geographies. Propeller has been studied in 25+ clinical studies totaling over 2,500 patients and has been deployed in more than 40 commercial programs across the US to date
Propeller users see consistent reductions in rescue inhaler use
Reductions in rescue inhaler use translate to better asthma and COPD control, lower healthcare costs, more days free from symptoms and higher patient quality of life
Propeller provides consistent levels of high medication adherence
Propeller programs show an average medication adherence of 46.6%, with many programs showing consistent adherence above 55%, compared to US average medication adherence of 22.1%
Propeller delivers consistent improvements in asthma control
On average, over 50% of patients with uncontrolled asthma achieve controlled status within one year of starting on Propeller. These consistent results are seen across randomized clinical studies and in diverse commercial programs
Positive ROI - Asthma
Uncontrolled asthma is expensive
Patients with uncontrolled asthma cost more each year compared to patients with controlled asthma
Higher direct asthma costs and higher total costs
Difference in direct asthma costs per year
(5 studies, n=142, 402)
(Controlled Asthma vs. Uncontrolled)
|Article||N||Asthma Direct Costs Savinga||Total Direct Costs Savings||Population|
|Ivanova et al, 2012||12,632||$893||$4,212||Privately insured patients with moderate or severe persistent asthma, ages 12-64.|
|Zeiger et al, 2008b,c||96,631||$356||$2,101||Privately insured asthmatic adults and children.|
|Szefler et al, 2011b||628||$1,359||NA||TENOR study patients, with severe asthma or mild / moderate asthma considered difficult-to-treat ages 6-12.|
|Sawicki et al, 2010c||28,595||$789||NA||Privately insured adults and children with asthma-related healthcare utilization or prescriptions.|
|Sullivan et al, 2007||3,916||$1,251||NA||Patients with severe or difficult-to-treat asthma, ages > 12.|
|Estimated cost savings:||$930d||$2,100e|
Zeiger, et al. 2008 (n=96,631)
- aAsthma-related direct costs defined as expenses from pharmaceuticals, inpatient hospitalizations, emergency department visits, and (except in Zeiger et al (2008) and Sawicki et al (2010)) unscheduled outpatient visits.
- bCost in uncontrolled is a weighted average of multiple uncontrolled groups.
- cCosts do not include outpatient medical visits.
- dSavings averaged across all studies.
- eFinal cost savings drawn from Zieger et al. (2008)
Propeller improves asthma control
Analyzing all patients on the Propeller System, we see that daily rescue inhaler use drops rapidly and persistently, with a 79% average reduction in rescue inhaler use at 1 year
Improving asthma control with Propeller yields positive ROI
Assumes 75% of people with uncontrolled asthma enrolled. Customers should see an average ROI of 2-5x depending on % improvement seen and use of direct vs. total costs
50% improvement seen across all patients on Propeller.
60% improvement seen in 495 patient randomized controlled clinical study.